Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages

Zura Bio Limited (NASDAQ:ZURA) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.75.

A number of equities analysts recently commented on the company. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a report on Friday. HC Wainwright reduced their price target on Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. Wall Street Zen upgraded Zura Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Oppenheimer lowered their target price on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th.

Zura Bio Trading Down 2.4%

Shares of NASDAQ ZURA opened at $4.08 on Friday. The firm has a market capitalization of $265.28 million, a PE ratio of -6.28 and a beta of 0.24. Zura Bio has a one year low of $0.97 and a one year high of $4.68. The business has a 50-day moving average price of $3.30 and a two-hundred day moving average price of $2.07.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Research analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Institutional Trading of Zura Bio

A number of hedge funds have recently modified their holdings of ZURA. Bank of America Corp DE lifted its stake in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. Nuveen LLC acquired a new position in Zura Bio during the first quarter worth $76,000. Forefront Analytics LLC lifted its holdings in shares of Zura Bio by 101.6% during the first quarter. Forefront Analytics LLC now owns 108,308 shares of the company’s stock valued at $140,000 after acquiring an additional 54,574 shares during the period. Armistice Capital LLC boosted its stake in shares of Zura Bio by 2.4% in the 1st quarter. Armistice Capital LLC now owns 1,536,000 shares of the company’s stock valued at $1,981,000 after purchasing an additional 36,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Zura Bio by 34.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,801,184 shares of the company’s stock worth $3,614,000 after purchasing an additional 723,933 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.